236 related articles for article (PubMed ID: 20615575)
21. [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations].
Zhu X; Liang L; Liu C; Yin W; Chen S; Cao B
Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):155-62. PubMed ID: 24581168
[TBL] [Abstract][Full Text] [Related]
22. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
23. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
26. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
27. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
28. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Lin JJ; Cardarella S; Lydon CA; Dahlberg SE; Jackman DM; Jänne PA; Johnson BE
J Thorac Oncol; 2016 Apr; 11(4):556-65. PubMed ID: 26724471
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs.
Jiang J; Gu Y; Liu J; Wu R; Fu L; Zhao J; Guan Y
Lung Cancer; 2016 Dec; 102():101-107. PubMed ID: 27987577
[TBL] [Abstract][Full Text] [Related]
30. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.
Chiu CH; Ho HL; Doong H; Yeh YC; Chen MY; Chou TY; Tsai CM
Oncotarget; 2015 Apr; 6(10):8407-17. PubMed ID: 25823662
[TBL] [Abstract][Full Text] [Related]
31. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
32. Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues.
Narumi S; Miki Y; Hata S; Ebina M; Saito M; Mori K; Kobayashi M; Suzuki T; Iwabuchi E; Sato I; Maemondo M; Endo C; Inoue A; Kondo T; Yamada-Okabe H; Ichinose M; Sasano H
Int J Biol Markers; 2015 May; 30(2):e234-42. PubMed ID: 25634032
[TBL] [Abstract][Full Text] [Related]
33. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
35. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi V; Balikó Z; Smuk G; László T; Szabó M; Ruzsics I; Mezősi E
Pathol Oncol Res; 2016 Oct; 22(4):755-61. PubMed ID: 27105879
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
37. The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations.
Hung MS; Lung JH; Lin YC; Fang YH; Hsieh MJ; Tsai YH
Medicine (Baltimore); 2016 Jun; 95(26):e3991. PubMed ID: 27368002
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
39. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
